13887-98-4

Basic information

• Product Name: 3,6,9-TRIOXAUNDECANEDIOIC ACID
• Synonyms: O,O'-OXYDIETHYLENE-DIGLYCOLIC ACID;TUDS;2,2'-[oxybis(2,1-ethanediyloxy)]bisacetic acid;TRIOXAUNDECANEDIOIC ACID;3,6,9-Trioxaundecanedioic acid (TUDS);Acetic acid, 2,2-oxybis(2,1-ethanediyloxy)bis-;2,2′-(Oxybis(2,1-ethandiyloxy))bisessigsure;3,6,9-Trioxa-1,11-undecanedioic acid
• CAS NO: 13887-98-4
• Molecular Formula: C₈H₁₄O₇
• Molecular Weight: 222.19
• EINECS: 237-655-9
• Product Categories: Heterocyclic Compounds
• Mol File: 13887-98-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 443.7 °C at 760 mmHg
• Flash Point: 178.3 °C
• Appearance: /
• Density: 1.3 g/mL at 20 °C(lit.)
• Vapor Pressure: 4.1E-09mmHg at 25°C
• Refractive Index: n20/D 1.470(lit.)
• Storage Temp.: Store below +30°C.
• Solubility: Soluble in Water, DMSO, DCM, DMF
• PKA: 3.09±0.10(Predicted)
• BRN: 1962084
• CAS DataBase Reference: 3,6,9-TRIOXAUNDECANEDIOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6,9-TRIOXAUNDECANEDIOIC ACID(13887-98-4)
• EPA Substance Registry System: 3,6,9-TRIOXAUNDECANEDIOIC ACID(13887-98-4)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• RIDADR: 1760
• WGK Germany: 1
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 13887-98-4(Hazardous Substances Data)

Usage

Description

3,6,9-TRIOXAUNDECANEDIOIC ACID, also known as PEG3-(CH2CO2H)2, is a PEG linker that contains two terminal carboxylic acid groups. It is characterized by its hydrophilic PEG spacer, which enhances solubility in aqueous media. The terminal carboxylic acids can react with primary amine groups in the presence of activators, such as EDC or HATU, to form a stable amide bond. This unique structure makes it a versatile compound with potential applications in various industries.

Uses

Used in Pharmaceutical Industry:
3,6,9-TRIOXAUNDECANEDIOIC ACID is used as a linker for drug conjugation due to its ability to form stable amide bonds with primary amine groups. This property allows for the creation of drug conjugates with improved solubility and bioavailability, enhancing the overall efficacy of the therapeutic agent.
Used in Drug Delivery Systems:
In the field of drug delivery, 3,6,9-TRIOXAUNDECANEDIOIC ACID is utilized as a component in the design of targeted drug delivery systems. Its hydrophilic PEG spacer and reactive carboxylic acid groups enable the conjugation of drugs to various carriers, such as nanoparticles or liposomes, for improved delivery and controlled release of the therapeutic agent.
Used in Chemical Synthesis:
3,6,9-TRIOXAUNDECANEDIOIC ACID is also used as an intermediate in the synthesis of various chemical compounds, taking advantage of its reactive carboxylic acid groups and hydrophilic PEG spacer. This allows for the creation of novel molecules with specific properties and applications in different industries, such as materials science, environmental science, and biotechnology.
Used in Cosmetics Industry:
In the cosmetics industry, 3,6,9-TRIOXAUNDECANEDIOIC ACID is employed as a component in the formulation of skincare products. Its hydrophilic nature and ability to form stable bonds with other molecules contribute to the development of products with enhanced moisturizing, emulsifying, and stabilizing properties, ultimately improving the overall performance and efficacy of the cosmetic formulation.

Flammability and Explosibility

Notclassified

InChI:InChI=1/C8H14O7/c9-7(10)5-14-3-1-13-2-4-15-6-8(11)12/h1-6H2,(H,9,10)(H,11,12)

Upstream product

• 112-60-7 Tetraethylene glycol 
• 211746-77-9 di-tert-butyl 2,2’-(2,2’-oxybis(ethane-1,2-diyl)bis(oxy))diacetate 
• 79-11-8 chloroacetic acid 
• 111-46-6 diethylene glycol 

Downstream Products

• 31255-25-1 tetra-glycolic acid dichloride 
• 31250-00-7 N,N'-bisphenyl-3,6,9-trioxaundecanedicarboxamide 
• 84308-20-3 (S)-2-[2-(2-{2-[((S)-1-Benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-methoxy]-ethoxy}-ethoxy)-acetylamino]-3-phenyl-propionic acid benzyl ester 
• 84293-32-3 (S)-2-[2-(2-{2-[((S)-1-Carboxy-2-phenyl-ethylcarbamoyl)-methoxy]-ethoxy}-ethoxy)-acetylamino]-3-phenyl-propionic acid 
• 41775-36-4 1,4,7,13-tetraoxa-10,16-diazacyclooctadecane 
• 638212-99-4 {2-[2-({4-[3-[3-(4-fluoro-phenyl)-3-hydroxy-propyl]-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl]-benzylcarbamoyl}-methoxy)-ethoxy]-ethoxy}-acetic acid 
• 883564-93-0 13,13-dimethyl-11-oxo-3,6,9,12-tetraoxatetradecan-1-oic acid 
• 146773-32-2 2-[2-[2-(2-benzyloxy-2-oxo-ethoxy)ethoxy]ethoxy]acetic acid 
• 1365543-84-5 (R)-4-((4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-9-imino-3,11,18,28,34-pentaoxo-20,23,26-trioxa-2,8,10,12,17,29,33-heptaazahexatriacontan-36-yl)(methyl)amino)pyridinium 2,2,2-trifluoroacetate 
• 1232884-88-6 ST₅₅₈₇ 
• 1232884-92-2 C₃₇H₄₆O₉ 
• 1612221-37-0 C₃₈H₅₆N₂O₉ 

Relevant articles and documents

Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma

We here report the synthesis of ethylene glycol N-interlinked imipramine dimers of various lengths from the tricyclic antidepressant desipramine via an amide coupling reaction followed by reduction with lithium aluminium hydride. The target molecules were found to be potent inhibitors of cellular viability while inducing cell type specific death mechanisms in three cancer cell lines including a highly chemoresistant Burkitt's lymphoma cell line. Basic amine analogues were found to be important for increased potency. Imipramine and desipramine were also tested for apoptotic activity and were found to be much less active than the novel dimeric compounds. Imipramine dimers were only found to be moderate inhibitors of the human serotonin transporter (hSERT) having IC50 values in the micromolar region whilst the induction of cell death occurred independently of hSERT expression. These results demonstrate the potential of newly designed and synthesised imipramines derivatives for use against malignant cells, including those resistant to standard chemotherapy.

Ether acid cobalt complex single crystal and preparation method as well as application thereof

The invention discloses ether acid cobalt complex single crystal, having a structure of [Co(L)(H2O)], wherein L is equal to di-ethoxy di-acetic acid. The invention also discloses a preparation method of the single crystal. According to the preparation method, a normal temperature volatilization method is adopted, i.e., L and Co(Ac)2.H2O are stirred in water for half an hour, and then are filtered, and filtrate is volatilized at normal temperature for two weeks, thus obtaining red blocky crystal suitable for X-ray single crystal diffraction, wherein the mol ratio of Co(Ac)2.H2O is 1 to 1. The invention further discloses application of the ether acid cobalt complex single crystal as a potential fluorescent material in detection on the adsorption quantity of a dye or an illuminating agent.

CHIRAL AMINOACID CONTAINING ACYCLIC LIGANDS-I. SYNTHESES AND CONFORMATIONS

Synthesis and spectral properties of optically active acyclic ligands, containing two (S)-phenylalanine residues (3a-f) are described.The synthesis is achieved by two different routes.Conformational studies in different solvents are performed by dilution and temperature-dependent experiments of 1H and 13C NMR spectroscopy.